Krystle L. Reagan, Terza Brostoff, Jully Pires, Amy Rose, Diego Castillo, Brian G. Murphy
{"title":"将口服莫仑吡韦作为自然流出的猫传染性腹膜炎一线治疗方法的开放标签临床试验。","authors":"Krystle L. Reagan, Terza Brostoff, Jully Pires, Amy Rose, Diego Castillo, Brian G. Murphy","doi":"10.1111/jvim.17187","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Before the discovery of effective antiviral drugs, feline infectious peritonitis (FIP) was a uniformly fatal disease of cats. Multiple antiviral treatments have been recognized, but optimization of treatment protocols is needed.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To evaluate the efficacy of PO molnupiravir (MPV; EIDD-2801) to treat effusive FIP.</p>\n </section>\n \n <section>\n \n <h3> Animals</h3>\n \n <p>Ten cats with naturally occurring effusive FIP and 10 historical control cats with effusive FIP treated with PO GS-441524.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A single-center, prospective, open-label longitudinal, non-inferiority trial with historical controls. Ten cats with FIP were enrolled and treated with PO MPV (10-15 mg/kg PO q12h) for 84 days. Cats were evaluated at 0, 6, and 16 weeks, and the proportion of cats in clinical remission at 16 weeks was determined. Survival and clinicopathologic features were compared with historical control cats with effusive FIP treated with PO GS-441524.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Eight of the 10 cats treated with MPV survived and were in remission at 16 weeks. The 2 non-survivors died in the first 24 hours of treatment. No adverse events that necessitated discontinuation of treatment were observed. Survival of cats treated with PO MPV was non-inferior to historic control cats treated with PO GS-441524 (5/9 [55%] survived), with a difference in survival of 25% (90% confidence interval, −9.3% to 59.3%). Clinicopathologic features associated with FIP normalized during the study period, and no differences in clinicopathologic data at each study time point were observed when comparing cats treated with MPV and GS-441524.</p>\n </section>\n \n <section>\n \n <h3> Conclusions and Clinical Importance</h3>\n \n <p>Molnupiravir is an effective antiviral treatment for effusive FIP.</p>\n </section>\n </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"38 6","pages":"3087-3094"},"PeriodicalIF":2.1000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.17187","citationCount":"0","resultStr":"{\"title\":\"Open label clinical trial of orally administered molnupiravir as a first-line treatment for naturally occurring effusive feline infectious peritonitis\",\"authors\":\"Krystle L. Reagan, Terza Brostoff, Jully Pires, Amy Rose, Diego Castillo, Brian G. Murphy\",\"doi\":\"10.1111/jvim.17187\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Before the discovery of effective antiviral drugs, feline infectious peritonitis (FIP) was a uniformly fatal disease of cats. Multiple antiviral treatments have been recognized, but optimization of treatment protocols is needed.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To evaluate the efficacy of PO molnupiravir (MPV; EIDD-2801) to treat effusive FIP.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Animals</h3>\\n \\n <p>Ten cats with naturally occurring effusive FIP and 10 historical control cats with effusive FIP treated with PO GS-441524.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A single-center, prospective, open-label longitudinal, non-inferiority trial with historical controls. Ten cats with FIP were enrolled and treated with PO MPV (10-15 mg/kg PO q12h) for 84 days. Cats were evaluated at 0, 6, and 16 weeks, and the proportion of cats in clinical remission at 16 weeks was determined. Survival and clinicopathologic features were compared with historical control cats with effusive FIP treated with PO GS-441524.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Eight of the 10 cats treated with MPV survived and were in remission at 16 weeks. The 2 non-survivors died in the first 24 hours of treatment. No adverse events that necessitated discontinuation of treatment were observed. Survival of cats treated with PO MPV was non-inferior to historic control cats treated with PO GS-441524 (5/9 [55%] survived), with a difference in survival of 25% (90% confidence interval, −9.3% to 59.3%). Clinicopathologic features associated with FIP normalized during the study period, and no differences in clinicopathologic data at each study time point were observed when comparing cats treated with MPV and GS-441524.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions and Clinical Importance</h3>\\n \\n <p>Molnupiravir is an effective antiviral treatment for effusive FIP.</p>\\n </section>\\n </div>\",\"PeriodicalId\":49958,\"journal\":{\"name\":\"Journal of Veterinary Internal Medicine\",\"volume\":\"38 6\",\"pages\":\"3087-3094\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.17187\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Veterinary Internal Medicine\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17187\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17187","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景：在发现有效的抗病毒药物之前，猫传染性腹膜炎（FIP）是一种致命的猫病。人们已经认识到多种抗病毒治疗方法，但仍需优化治疗方案：评估 PO molnupiravir（MPV；EIDD-2801）治疗流脓性 FIP 的疗效：动物：10 只患有自然流出性 FIP 的猫和 10 只患有流出性 FIP 并接受 PO GS-441524 治疗的历史对照组猫：方法：单中心、前瞻性、开放标签纵向非劣效性试验，并设历史对照。十只患有 FIP 的猫被纳入试验，接受 PO MPV（10-15 mg/kg PO q12h）治疗 84 天。在 0、6 和 16 周时对猫咪进行评估，并确定 16 周时临床缓解的猫咪比例。将存活率和临床病理特征与使用 PO GS-441524 治疗流脓性 FIP 的历史对照组进行比较：结果：接受 MPV 治疗的 10 只猫中有 8 只存活下来，并在 16 周时病情得到缓解。2只未存活的猫在治疗后24小时内死亡。没有观察到需要停止治疗的不良反应。接受 PO MPV 治疗的猫的存活率不低于接受 PO GS-441524 治疗的历史对照组猫（5/9 [55%] 存活），存活率相差 25%（90% 置信区间，-9.3% 至 59.3%）。在研究期间，与 FIP 相关的临床病理特征趋于正常，在比较使用 MPV 和 GS-441524 治疗的猫时，未观察到各研究时间点的临床病理数据存在差异：结论和临床意义：莫鲁拉韦是治疗流脓型 FIP 的有效抗病毒药物。
Open label clinical trial of orally administered molnupiravir as a first-line treatment for naturally occurring effusive feline infectious peritonitis
Background
Before the discovery of effective antiviral drugs, feline infectious peritonitis (FIP) was a uniformly fatal disease of cats. Multiple antiviral treatments have been recognized, but optimization of treatment protocols is needed.
Objective
To evaluate the efficacy of PO molnupiravir (MPV; EIDD-2801) to treat effusive FIP.
Animals
Ten cats with naturally occurring effusive FIP and 10 historical control cats with effusive FIP treated with PO GS-441524.
Methods
A single-center, prospective, open-label longitudinal, non-inferiority trial with historical controls. Ten cats with FIP were enrolled and treated with PO MPV (10-15 mg/kg PO q12h) for 84 days. Cats were evaluated at 0, 6, and 16 weeks, and the proportion of cats in clinical remission at 16 weeks was determined. Survival and clinicopathologic features were compared with historical control cats with effusive FIP treated with PO GS-441524.
Results
Eight of the 10 cats treated with MPV survived and were in remission at 16 weeks. The 2 non-survivors died in the first 24 hours of treatment. No adverse events that necessitated discontinuation of treatment were observed. Survival of cats treated with PO MPV was non-inferior to historic control cats treated with PO GS-441524 (5/9 [55%] survived), with a difference in survival of 25% (90% confidence interval, −9.3% to 59.3%). Clinicopathologic features associated with FIP normalized during the study period, and no differences in clinicopathologic data at each study time point were observed when comparing cats treated with MPV and GS-441524.
Conclusions and Clinical Importance
Molnupiravir is an effective antiviral treatment for effusive FIP.
期刊介绍：
The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
